Joshua Cohen

Non-profit leader, organizational change agent, social justice advocate. DO GOOD. BE KIND.

Categories
N/A
Content Types
N/A
More Information
Location|Languages
Publications
N/A

Published Content

63
forbes.com
Article
ICER's Growing Impact On Drug Pricing And Reimbursement
April, 17 2019
forbes.com
Article
PBM Executives Questioned On Drug Pricing Practices By Senate Finance Committee
April, 15 2019
forbes.com
Article
How Are Gene Therapies Going To Get Paid For?
April, 12 2019
forbes.com
Article
Collateral Damage From The Trump Administration's Decision To Invalidate ACA
March, 27 2019
forbes.com
Article
Rising Out-Of-Pocket Costs For Insulin Indicates Market Failure
March, 22 2019
forbes.com
Article
Hospital Pricing Practices: Transparency And Clarity Are Lacking
March, 19 2019
forbes.com
Article
Healthcare Reformers Should Look To Europe For Feasible Alternatives To Medicare For All
March, 14 2019
forbes.com
Article
Esketamine Faces Challenges In Its Quest To Be A Breakthrough Drug Against Suicidal Ideation
March, 11 2019
forbes.com
Article
FDA Commissioner Gottlieb's Resignation Leaves A Void
March, 7 2019
forbes.com
Article
HHS's Multi-Pronged Approach To Lower Drug Prices: Will It Work?
February, 22 2019
forbes.com
Article
Medicare For All: Is The U.S. Headed In That Direction?
February, 19 2019
forbes.com
Article
Medicinal Cannabis: More Data Needed On Clinical- And Cost-Effectiveness
February, 14 2019
forbes.com
Article
New Reinsurance Model In Medicare Part D
February, 11 2019
forbes.com
Article
Pouring Billions Of Dollars Into Marketing Of Drugs
February, 7 2019
forbes.com
Article
Rebates To The Dustbin Of History?
February, 4 2019
forbes.com
Article
States In Driver's Seat On Healthcare Reform
February, 1 2019
forbes.com
Article
The Importance Of Patient-Centric Opioid Prescribing Guidelines
January, 23 2019
forbes.com
Article
FDA's Banner Year For Approvals: Will Market Access To New Drugs Follow Suit?
January, 21 2019
forbes.com
Article
Trump Administration Throws Down Gauntlet On Drug Prices
January, 16 2019
forbes.com
Article
A QALY Is A QALY Is A QALY, Or Is It?
January, 14 2019
forbes.com
Article
Partial Government Shutdown's Impact On FDA Drug Approvals
January, 10 2019
forbes.com
Article
Smartphones Could Boost OTC Drug Utilization And Numbers Of Rx-To-OTC Switches, Too
January, 10 2019
forbes.com
Article
Unmet Medical Needs Persist Across Many Diseases
December, 26 2018
forbes.com
Article
Looking Into A Crystal Ball: Some Healthcare Predictions For 2019
December, 19 2018
forbes.com
Article
Texas Judge Deals Obamacare A Major Blow
December, 16 2018
forbes.com
Article
Value-Based Pricing And Reimbursement: Still More Promise Than Reality
December, 13 2018
forbes.com
Article
Is It Rational For Employers And Payers To Be Hooked On Prescription Drug Rebates?
December, 10 2018
forbes.com
Article
HHS Making Bundled Payments Mandatory Again
December, 5 2018
forbes.com
Article
Politicians' Narrow Focus On Prescription Drug Spending Is Myopic
December, 3 2018
forbes.com
Article
For Some Patients Financial Toxicity Is Real And Getting Worse
November, 26 2018
forbes.com
Article
4 Million Dollars Or Your Life
November, 19 2018
forbes.com
Article
Medicare Part D Changes: Empowering The Plan, Not Necessarily The Beneficiary
November, 15 2018
forbes.com
Article
Specialty Generics: Barriers To Uptake
November, 12 2018
forbes.com
Article
Risk-Sharing Arrangements May Boost Fortunes Of Certain Prescription Drugs
November, 7 2018
forbes.com
Article
Priority Review Vouchers Revitalizing Neglected Disease Drug Development
November, 5 2018
forbes.com
Article
The New Anti-Flu Drug Xofluza's Value Proposition
November, 1 2018
forbes.com
Article
Trump's Proposed Medicare Drug Pricing Experiment Stokes Fears Of Price Controls
October, 28 2018
forbes.com
Article
Edge In U.S. Cancer Drug Development Spurred By Regulatory And Reimbursement Policies
October, 22 2018
forbes.com
Article
Improving Drug Price Transparency: From Removing Pharmacy Gag Clauses To Reforming The Rebate System
October, 17 2018
forbes.com
Article
Measuring Well-Being: It's More Than GDP
October, 15 2018
forbes.com
Article
Why It's Not So Simple To Standardize The Guides Insurers Use To Pay For Off-Label Cancer Drugs
October, 10 2018
forbes.com
Article
Possible Removal Of Pre-Existing Conditions Protections
October, 8 2018
forbes.com
Article
Cigna And Express Scripts Deal: Virtues Of Vertical Integration
October, 3 2018
forbes.com
Article
Why Payers Sometimes Restrict Access To Single Tablet Regimens For HIV Patients
October, 1 2018
forbes.com
Article
To Include Or Not Include Drug Prices In DTC Ads
September, 24 2018
forbes.com
Article
Will CVS Caremark Make ICER The American NICE?
September, 20 2018
forbes.com
Article
Medicare Advantage Plan Proposed Use Of Step Therapy For Part B Drugs
September, 17 2018
forbes.com
Article
The Curious Case Of Gleevec Pricing
September, 12 2018
forbes.com
Article
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
September, 10 2018
forbes.com
Article
Tanezumab's Phase 3 Results: A Promising Sign For Non-Opioid Pain Treatments
September, 6 2018
Authorship Stats
1Sites63Projects42,812Words
About
Joshua Cohen is a writer who has produced content for forbes.com
Key Phrases
Drug Prices, Prescription Drug, Trump Administration, Cancer Drugs, Drug Administration, Health Insurance, List Prices, Single Payer, Prescription Drugs, Healthcare System
© ClearVoice, Inc.